Skip to content

Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis

Evaluation of Cognitive, Metacognitive, Social Cognition and Trauma Related-Variables in Patients With Psychosis Receiving VR-Based Avatar Therapy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07091344
Acronym
Meta-VR-AVATAR
Enrollment
30
Registered
2025-07-29
Start date
2024-03-01
Completion date
2026-12-30
Last updated
2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Disorders, Treatment Resistant Hallucinations

Keywords

VR-based Avatar Therapy, cognition, metacognition, social cognition, psychosis, schizophrenia spectrum disorders, auditory hallucinations, trauma and psychosis, emotion recognition, Personalized therapy

Brief summary

This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations. In addition to the primary intervention, participants will be assessed using validated tools for emotion recognition, attributional style, theory of mind, neurocognition, and metacognition. The study also explores the potential role of trauma as a predisposing factor. Assessments will be conducted at four time points: screening (week 0), baseline (week 12), intervention period (weeks 12-24), and post-therapy follow-up (week 24). By investigating these variables, this study seeks to better understand their impact on treatment outcomes and contribute to the development of personalized therapeutic approaches.

Detailed description

This interventional study investigates the impact of cognitive, metacognitive, and social cognition variables on the outcomes of VR-based Avatar Therapy for auditory hallucinations in patients with psychosis. Participants will be assessed at four key time points: screening (week 0), baseline (week 12), during the intervention (weeks 12-24), and post-therapy (week 24). The intervention consists of 7 individual VR-based Avatar Therapy sessions delivered over 12 weeks. The therapy uses virtual reality to externalize and reframe distressing auditory hallucinations, helping participants develop more adaptive responses. In addition to evaluating the therapy's effectiveness, the study incorporates validated tools to measure: Social Cognition: Emotional recognition (Test de Reconocimiento Emocional), attributional style (AIHQ), theory of mind (Hinting Task), and social perception (SFRT-2). Metacognition: Insight and cognitive monitoring using the BCIS and CBQ. Cognition: Neuropsychological functions, including attention, flexibility, and memory (SCIP, Stroop, TMT, and Vocabulary WAIS). Trauma as a predisposing factor: Using the Childhood Trauma Questionnaire (CTQ). By examining these variables, the study aims to deepen the understanding of their influence on treatment outcomes and inform the development of personalized therapeutic approaches for psychosis.

Interventions

BEHAVIORALVR-Based Avatar Therapy with Cognitive and Metacognitive Assessments

VR-Based Avatar Therapy is a 12-week intervention designed to help patients with psychosis manage distressing auditory hallucinations. The therapy consists of 7 individual sessions using virtual reality (VR) technology to externalize the auditory hallucinations, allowing patients to interact with a computer-generated avatar representing their dominant voice. In addition to standard therapy, participants will undergo assessments of cognition, metacognition, and social cognition to explore their impact on treatment outcomes. These assessments include measures of emotion recognition, attributional style, theory of mind, cognitive flexibility, and trauma history. Sessions are conducted using VR headsets and noise-canceling headphones to enhance immersion, and patients receive ongoing therapeutic guidance throughout the process.

Sponsors

Fundació Sant Joan de Déu
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study employs a single-group pre-post interventional design with a waiting list control phase. All participants will initially undergo a 12-week waiting period (control phase) starting at screening (week 0). Baseline assessments will be conducted at week 12, followed by a 12-week intervention phase where participants receive 7 individual VR-based Avatar Therapy sessions. Post-therapy assessments will be conducted at week 24 to evaluate changes in auditory hallucinations and associated cognitive, metacognitive, and social cognition variables. This design allows for a comprehensive evaluation of both the direct effects of the intervention and the potential moderating or mediating role of the measured variables on therapeutic outcomes.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\*\*Inclusion Criteria:\*\* * Adults aged 18 years or older. * Diagnosis of schizophrenia spectrum disorder according to DSM-5 criteria. * Experience of persistent auditory hallucinations for at least 3 months (PANSS hallucination score ≥ 3). * Stable medication dosage for at least 4 weeks prior to recruitment. * Fluent in the spoken language of the study site (Spanish). * Able to provide informed consent. * Regular psychiatric follow-up care. \*\*

Exclusion criteria

\*\* * Inability to identify a dominant voice for Avatar Therapy intervention. * Intellectual disability based on medical history. * Active substance abuse. * Central nervous system injury or neurological disorders affecting cognitive performance. * Severe visual impairment that precludes the use of VR technology. * Aversion to virtual reality or prior experience of simulator sickness. * Current suicidal ideation or risk. * Lack of cooperation or inability to comply with study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Change in Working Memory ScoreWeek 0, Week 12, Week 24Working memory assessed by the WAIS-IV Digit Span. Scaled score range: 1-19; higher scores = better performance.
Change in Cognitive Flexibility ScoreWeek 0, Week 12, Week 24Mental flexibility assessed with the Trail Making Test, Part B. Outcome: time in seconds (maximum 300 seconds); lower times = better performance.
Change in Global Cognitive Performance ScoreWeek 0, Week 12, Week 24Global cognition assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP). Total score range: 0-75; higher = better cognitive performance.
Change in Emotion Recognition ScoreWeek 0, Week 12, Week 24Change in participants' ability to recognize basic emotions using the Faces Test. Score range: 0-20; higher scores = better emotion recognition.
Change in Executive Functioning ScoreWeek 0, Week 12, Week 24.Change in Executive Functioning Score Executive functioning assessed with the Wisconsin Card Sorting Test (WCST). Outcomes include number of categories completed (0-6; higher = better) and number of perseverative errors (no fixed maximum; lower = better). The task ends when the participant completes 6 categories or after all 128 cards are placed.
Change in Attributional Style ScoreWeek 0, Week 12, Week 24Attributional style in ambiguous social situations assessed with the Ambiguous Intentions Hostility Questionnaire (AIHQ). Score range: 0-100; higher scores = greater hostile attribution/conviction.
Change in Theory of Mind ScoreWeek 0, Week 12, Week 24Ability to infer others' intentions measured by the Hinting Task. Score range: 0-6; higher scores = better Theory of Mind.
Change in Metacognition ScoreWeek 0, Week 12, Week 24Cognitive insight measured by the Beck Cognitive Insight Scale (BCIS): Self-reflectiveness (0-27; higher = better) and Self-certainty (0-21; higher = worse).

Other

MeasureTime frameDescription
Change in Verbal Skills ScoreWeek 0, Week 12, Week 24Verbal ability assessed by WAIS-IV Vocabulary. Scaled score range: 1-19; higher scores = better verbal ability.
Childhood Trauma Exposure (Baseline moderator)Week 0 (one-time measure).Childhood trauma at baseline measured with the CTQ-SF. Total score range: 25-125; higher = greater trauma exposure.

Countries

Spain

Contacts

Primary ContactSusana Ochoa, PhD
susana.ochoa@sjd.es+34936406350
Backup ContactLuciana Díaz-Cutraro, PhD
luciana.diaz@sjd.es+34936406350

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026